|
Explanatory variable
|
Metabolic syndrome by using IDF criteria
|
Metabolic syndrome by using NCEP-ATP criteria
|
|---|
|
Presence of MetS = N (%)
|
COR (95 % CI)
|
AOR (95 % CI)
|
Presence of MetS = N (%)
|
COR (95 % CI)
|
AOR (95 % CI)
|
|---|
|
BMI (kg/m2)
|
|
≤25
|
30 (16.2)
|
1.00
|
1.00
|
21 (11.3)
|
1.00
|
1.00
|
|
>25
|
15 (8.1)
|
3.0 (1.3–6.5)
|
3.8 (1.5–9.8)
|
12 (6.5)
|
3.2 (1.4–7.4)
|
3.4 (1.3–9.2)
|
|
p value
| |
0.006
|
0.005
| |
0.006
|
0.01
|
|
Gender
|
|
Male
|
6 (3.2)
|
1.00
|
1.00
|
12 (6.5)
|
1.00
|
1.00
|
|
Female
|
39 (21.1)
|
5.1 (2.0–12.9)
|
7.9 (2.6–24.1)
|
21 (11.3)
|
1.0 (0.47–2.3)
|
1.5 (0.24–1.8)
|
|
p value
| |
<0.0001
|
<0.0001
| |
0.19
|
0.43
|
|
Age (years)
|
|
≤40
|
41 (22.1)
|
1.00
|
1.00
|
25 (13.5)
|
1.00
|
1.00
|
|
>40
|
4 (2.1)
|
0.66 (0.21–2.0)
|
2.0 (0.45–9.5)
|
8 (4.3)
|
3.1 (1.2–8.3)
|
3.8 (1.0–13.7)
|
|
p value
| |
0.21
|
0.35
| |
0.02
|
0.04
|
|
ART use (months)
|
|
≤48
|
22 (11.9)
|
1.00
|
1.00
|
20 (10.8)
|
1.00
|
1.00
|
|
>48
|
23 (12.4)
|
1.8 (0.95–3.7)
|
2.3 (1.0–5.4)
|
13 (7.0)
|
0.99 (0.46–2.1)
|
0.8 (0.32–1.9)
|
|
p value
| |
0.07
|
0.04
| |
0.20
|
0.33
|
|
Cigarette
|
|
Never smoke
|
43 (23.2)
|
1.00
|
1.00
|
28 (15.1)
|
1.00
|
1.00
|
|
Still smoking
|
2 (1.1)
|
0.26 (0.06–1.1)
|
0.17 (0.03–1.0)
|
5 (2.7)
|
1.3 (0.45–3.9)
|
0.47 (0.10–2.1)
|
|
p value
| |
0.08
|
0.05
| |
0.18
|
0.33
|
|
Education
|
|
Illiterate
|
1 (0.5)
|
1.00
|
1.00
|
3 (1.6)
|
1.00
|
1.00
|
|
Primary
|
22 (11.9)
|
6.7 (0.8–53.3)
|
10.1 (1.1–94)
|
15 (8.1)
|
1.2 (0.31–4.7)
|
0.85 (0.17–4.3)
|
|
p value
| |
0.07
|
0.04
| |
0.16
|
0.24
|
|
Secondary and above
|
22 (11.9)
|
6.2 (0.79–49.9)
|
10.9 (1.1–104)
|
15 (8.1)
|
1.1 (0.3–4.4)
|
1.1 (0.45–2.8)
|
|
p value
| |
0.08
|
0.04
| |
0.21
|
0.37
|
-
ART antiretroviral therapy, COR crude odds ratio, AOR adjusted odds ratio, CI confidence interval, BMI body mass index, EFV Efavirenz, NVP Nevirapine, NNRTI non nucleoside reverse transcriptase inhibitors
